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Abstract 48 
Introduction: The Nutritional Risk Screening 2002 (NRS 2002) identifies patients at 49 
risk of malnutrition. We studied the prognostic implications of this score with regard to 50 
short-term and long-term clinical outcomes in a well-characterised cohort of medical 51 
inpatients from a previous trial.  52 
Methods: This is a secondary analysis of an investigator-initiated, prospective 53 
randomised controlled multicenter trial in Switzerland (EFFORT) that compared the 54 
effects of an individualised nutritional support intervention with standard of care. We 55 
investigated associations between admission NRS and several short-term and long-56 
term outcomes using multivariable regression analyses. 57 
Results: Of the 2,028 patients, 31% had an NRS of 3, 38% of 4 and 31% of ≥5 58 
points, and 477 (24%) died during the 180 days of follow-up. For each point increase 59 
in NRS, we found a stepwise increase in risk of 30-day mortality (adjusted Hazard 60 
Ratio (HR) 1.22 (95% CI 1.00 to 1.48), p=0.048) and 180-day mortality (adjusted HR 61 
1.37 (95% CI 1.22 to 1.55), p<0.001). NRS was associated with length of hospital 62 
stay (adjusted difference of 0.60 days per NRS point increase, 95%CI 0.23 to 0.97, 63 
p=0.002) and functional outcomes at 180 days (adjusted decrease in Barthel index of 64 
-4.49 points per NRS point increase, 95%CI -6.54 to -2.45, p<0.001). In a subgroup 65 
analysis, associations of NRS and short-term adverse outcomes were less 66 
pronounced in patients receiving nutritional support (intervention group) compared to 67 
control group patients (adjusted HR for 30-day mortality 1.12 [95%CI 0.83 to 1.52, 68 
p=0.454] vs. 1.33 [95%CI 1.02 to 1.72, p=0.032]). 69 
Conclusion: The NRS is a strong and independent risk score for malnutrition-70 
associated mortality and adverse outcomes over 180 days. Our data provide strong 71 
evidence that the nutritional risk, however, is modifiable and can be reduced by the 72 
provision of adequate nutritional support. 73 
Introduction 74 
Malnutrition is a common condition in medical inpatients affecting approximately 30-75 
50% in the western patient population [1-3]. Patients with poor nutritional status are 76 
more likely to suffer from adverse outcomes, have an elevated risk of mortality and 77 
morbidity, as well as experience significant socioeconomic implications [4-7]. 78 
Importantly, recent studies have found that malnutrition risk factors in medical 79 
inpatient populations are at least partly modifiable [8-10]. More specifically,  two trials 80 
reported positive outcomes on mortality associated with a nutritional intervention [11, 81 
12]. The placebo-controlled NOURISH (Nutrition effect On Unplanned Readmissions 82 
and Survival in Hospitalized patients) trial found a significant reduction in mortality 83 
over 90 days in medical inpatients treated with a high protein oral nutrition 84 
supplement [13]. Similarly, the recent EFFORT (Effect of Early Nutritional Support on 85 
Frailty, Functional Outcomes and Recovery of Malnourished Medical Inpatients) trial 86 
found a reduction in the risk for severe complications and mortality associated with 87 
the use of nutritional support compared to a control group not receiving additional 88 
nutritional support [11]. These findings have provided conclusive evidence to support 89 
current guideline recommendations regarding early screening of patients for 90 
malnutrition upon hospital admission and the use of nutritional support intervention 91 
for at-risk patients [14-16]. 92 
For this purpose, several screening tools for malnutrition have been proposed and 93 
validated in different patient populations [17, 18]. Of these, the Nutritional Risk 94 
Screening (NRS 2002) has become particularly well established for the medical 95 
inpatient population [19, 20]. NRS includes assessment of the patient’s nutritional 96 
status (based on weight loss, Body Mass Index (BMI) and general condition or food 97 
intake) and disease severity (stress metabolism due to the degree of disease), and is 98 
associated with higher risk for adverse outcomes. Each section is scored from 0 to 3 99 
points, and patients receive an extra point if they are 70 years or older [21-23]. 100 
Earlier observational retrospective studies also found that the NRS has prognostic 101 
implications and is associated with short-term and long-term mortality [24, 25]. It 102 
remains unclear, however, if the association can be explained by other disease-103 
related factors, or whether the type of nutritional support may influence the 104 
connection between NRS and outcome.  105 
Herein, we hypothesized that an elevated risk for malnutrition, as assessed by the 106 
NRS, is associated with an increased long-term risk for mortality and that this risk is 107 
modifiable through the provision of individual nutritional support. To test this 108 
hypothesis, we performed a secondary analysis of a prospective, multicentre, 109 
randomised trial [11] to investigate the association of NRS with different clinical 110 
health outcomes at short-term and long-term follow-up, and studied the differences 111 
according to the nutritional support provided to patients.    112 
Methods 113 
Study design and setting 114 
This study is a secondary analysis of the overall EFFORT study population, an 115 
investigator-initiated, non-commercial, prospective and open-label randomised trial 116 
that compared the effects of individualised nutritional support intervention versus no 117 
nutritional support on medical outcomes in patients at nutritional risk (as assessed by 118 
the NRS). The trial protocol and the main results have been published elsewhere [26]. 119 
The ethics committee of northwest / central Switzerland (EKNZ) approved the study 120 
protocol in January 2014 (EKNZ; 2014_001). The eight participating sites were 121 
secondary and tertiary care hospitals in Switzerland and included the University 122 
Clinic in Aarau, the University Hospital in Bern, the Cantonal hospitals in Lucerne, 123 
Solothurn, St. Gallen, Muensterlingen and Baselland, and the hospital in Lachen. 124 
Patients were enrolled between April 2014 and February 2018. 125 
 126 
Patient population 127 
Adult patients with a NRS total score ≥3 points, an expected length of hospital stay 128 
(LOS) >4 days and willingness to provide informed consent were eligible. Exclusion 129 
criteria were defined as initial admission to an intensive care unit or surgical unit; the 130 
inability to tolerate oral nutrition intake; nutritional support received at time of 131 
admission; patients with a terminal condition; admission to hospital due to anorexia 132 
nervosa, acute pancreatitis, acute liver failure, cystic fibrosis, stem cell 133 
transplantation or gastric bypass surgery; contraindications for nutritional support; 134 
and previous inclusion in the trial. 135 
 136 
 137 
 138 
Outcomes 139 
The primary endpoint of this study was all-cause mortality from inclusion in the trial 140 
up to day 30 and day 180.  141 
Secondary endpoints included the composite endpoint adverse events (all-cause 142 
mortality, admission to the intensive care , readmission and major complications) as 143 
well as major complications (nosocomial infection or abscess requiring antibiotic 144 
treatment, major cardiovascular events, acute renal failure); economic outcome 145 
including total LOS, non-elective hospital readmission (defined as non-scheduled 146 
hospital readmission after discharge), and admission to the intensive care unit from 147 
the medical ward. Functional outcomes included functional impairment (assessed 148 
with the Barthel scale), quality of life (European Quality of Life 5 Dimensions Index 149 
(assessed with the European Quality of Life 5 Dimensions Index (EQ-5D)) and 150 
visual-analogue scale [EQ-5D VAS]), fractures, and accidental fall events. All 151 
outcomes were defined and assessed as short-term (30 days) and long-term (180 152 
days) outcomes. To assess primary and secondary endpoints, all patients were 153 
contacted by blinded study nurses for a structured telephone interview after 30 days 154 
and 180 days. The survival status of all patients during follow-up was confirmed 155 
either by family members or the patient`s family physician. 156 
The Barthel scale was used to assess the performance of activities of daily living. 157 
Functional impairment was defined as a decline of 10% or more in functional status. 158 
The EuroQol Group 5- Dimension Self-Report Questionnaire, which ranges from 0 to 159 
1, with higher scores indicating better life quality and EQ-5D VAS, which scores from 160 
0 to 100, with higher scores indicating better health status, were used to rate quality 161 
of life [11].  162 
Nutritional status and procedures 163 
Nutritional status was assessed as recommended by nursing staff within 24-48 hours 164 
after hospital admission using the NRS score[18, 27]. We scored for each predictor 165 
of the NRS (i.e. patient’s nutritional status (based on weight loss, Body Mass Index 166 
[BMI] and general condition or food intake) and disease severity) between 0 to 3 167 
points, and added an extra point for patients aged 70 years or older. A NRS total 168 
score of ≥ 3 points was considered "at risk" for malnutrition. We then divided the 169 
study population into three groups (i.e., moderate risk, high risk, very high risk) 170 
according to NRS (3 points; 4 points; ≥5 points). 171 
 172 
Nutritional support provided during the trial 173 
Nutritional support during the trial differed according to randomisation of patients, and 174 
details of the intervention have been published [26]. In summary, in the intervention 175 
group, nutritional support was initiated as soon as possible after trial inclusion. 176 
Patients received individualised nutritional support to reach protein and energy 177 
requirements according to a previously published consensus protocol and under the 178 
guidance of a registered dietician [15]. Energy requirements were predicted using the 179 
weight-adjusted Harris-Benedict equation [28]. Daily protein intake was set at 1.2–1.5 180 
g/kg body weight, [29] with lower targets for patients with acute renal failure but 181 
without need of renal replacement therapy (0.8 g per kg of body weight). An 182 
individual nutritional plan was developed for each patient that was initially based on 183 
oral nutrition provided by the hospital kitchen and further increased to enteral tube 184 
feeding or parenteral feeding if at least 75% of energy and protein targets could not 185 
be reached within 5 days by oral (or enteral) feeding. In total 8, respectively 12 186 
patients received enteral or parenteral nutrition. Nutritional intake was reassessed 187 
every 24–48 h throughout the hospital stay and compliance to the nutrition care plan 188 
was reinforced. Upon discharge from hospital, patients received dietary counselling 189 
and, if indicated, a prescription for oral nutritional supplements to be taken in the 190 
outpatient setting.  191 
Control group patients received standard hospital food according to their ability and 192 
desire to eat, with no additional nutritional consultation and no recommendation for 193 
supplementary nutritional support.  194 
 195 
Study aims 196 
The overall aim of this analysis was to investigate the prognostic implications of NRS 197 
in connection with short-term and long-term clinical outcomes in a well-characterised 198 
cohort of patients from the EFFORT intervention trial, as well as to compare 199 
differences when stratifying patients based on nutritional support received.  200 
 201 
Sample size and statistical analyses 202 
For this secondary analysis looking at associations of NRS and long-term mortality 203 
within 180 days, we used patients previously included in a randomized trial and the 204 
sample size was therefore based on the available number of patients included in the 205 
initial trial. Still, with 477 patients reaching the primary endpoint, this sample provides 206 
adequate power to support over 47 degrees of freedom in the models. We thus 207 
assume that inclusion of up to 47 covariates is possible in the regression models. 208 
Categorical variables are expressed as counts (percentages, standard deviations 209 
(SD)) and continuous variables as medians (interquartile ranges [IQR], 25th and 75th 210 
percentiles). 211 
We calculated regression models adjusted for important confounders (sex, 212 
comorbidities, admission diagnosis, study centre and randomisation) to explore the 213 
association between the NRS and several short-term and long-term outcomes. 214 
Models were not additionally adjusted for age as this variable is already a part of 215 
NRS. We used Cox regression models for time-to-event data with recorded hazard 216 
ratios (HRs), logistic regression for binary outcomes with recorded odds ratios (ORs) 217 
and linear regression for continuous outcomes with recorded coefficients. We also 218 
calculated Kaplan-Meier survival curves to present the results visually.  219 
Finally, we conducted different analyses according to the pre-specified subgroups, 220 
stratifying patients based on age, sex, and main admission diagnosis, as well as 221 
those receiving individual nutrition support for different short-term outcomes.  222 
All statistical analyses were performed with STATA 15.1 (Stata Corp, College 223 
Station, TX, USA). A P value <0.05 (for a 2-sided test) was considered to indicate 224 
statistical significance. 225 
  226 
Results 227 
We included all 2,028 patients who were enrolled in the EFFORT trial. A total of 624 228 
(31%) patients had a NRS score of 3 points, 775 (38%) a NRS score of 4 points and 229 
629 (31%) a NRS score of ≥5 points. Overall, the median age of the patients was 230 
72.6 years and 1,064 (52%) were male. When comparing patients with NRS of 3, 4 231 
and ≥5 points, we found significant differences in regard to age, weight, admission 232 
diagnosis, and comorbidities. More detailed patient baseline characteristics, stratified 233 
by NRS and by mortality at 180 days, are shown in Table 1. 234 
 235 
Association of NRS with short-term and long-term mortality (primary endpoint) 236 
At 30-day and 180-day follow-up, a total of 173 patients (9%) and 477 patients (24%) 237 
respectively had died. Mortality showed a stepwise increase consistent with higher 238 
NRS scores at short term and long term follow-up. This was also confirmed in a 239 
multivariable regression analysis with an adjusted HR of 1.22 (1.00 to 1.48, p=0.048) 240 
for mortality at 30 days and an adjusted HR of 1.37 (1.22 to 1.55, p<0.001) for 180-241 
day mortality (Table 2).  242 
These results were also confirmed in Kaplan-Meier survival estimates showing a 243 
higher likelihood for mortality with increasing NRS scores (Figure 1).  244 
 245 
Associations of NRS with secondary endpoints  246 
We also investigated associations between NRS and different secondary endpoints 247 
(Table 2). We observed a stepwise increase in the incidence of adverse outcomes 248 
within 30 days - from 22.6% (3 points) to 24.0% (4 points) to 28.1% (5 points and 249 
more) with an unadjusted OR of 1.16 (95% CI 1.02 to 1.32, p=0.023) but without 250 
remaining significant after multivariate adjustment (p=0.130). There was also a 251 
significant increase in mean LOS (from 8.8 to 9.8 to 9.9 days, respectively) with an 252 
(adjusted) increase of 0.6 days (95% CI 0.23 to 0.97) p=0.002) per increase in NRS 253 
point. In addition, there was an increase in the risk for impairment of activities of daily 254 
living as defined by Barthel scale at days 30 and 180 (coefficient of -0.65 points (95% 255 
CI -1.18 to -0.11, p=0.018) for day 30 and -7.52 points (95% CI -9.63 to -5.39, 256 
p<0.001) for day 180. Similar results were found for impairment in quality of life within 257 
180 days, as measured by EQ-5D and the EQ-5D VAS.  258 
 259 
Subgroup analysis for the primary endpoint 260 
We also performed several pre-planned subgroup analyses to investigate whether 261 
the association between NRS and mortality was dependent on age, sex and main 262 
admission diagnosis. Figure 2 shows associations of the NRS and 180-day mortality 263 
within these different subgroups. Overall, results were similar, with little difference 264 
between groups.  265 
 266 
Subgroup analysis regarding effects of nutritional support 267 
Finally, to understand whether the nutritional risk is modifiable through the provision 268 
of nutritional support, we performed a subgroup analysis comparing associations of 269 
NRS and outcomes stratified by nutritional support received during the trial 270 
(nutritional support group vs. control group) (Table 3, Figure 3). We found a stronger 271 
association of NRS and mortality within 30 days for patients not receiving nutritional 272 
support (i.e. control group patients) compared to patients receiving nutritional support 273 
(HR of 1.43 (95% CI 1.11 to 1.85) vs. 1.20 (95% CI 0.89 to 1.61). Results were 274 
similar for other endpoints including overall adverse outcomes, non-elective hospital 275 
readmission, and admission to an intensive care unit. 276 
 277 
 278 
Discussion 279 
The main findings of this secondary analysis from a recent multicentre trial are 280 
twofold. First, we found associations of NRS with different adverse clinical outcomes 281 
at short-term and long-term follow-up, which proofed to be independent of important 282 
confounders in multivariate analysis and showed robust results in different subgroup 283 
analyses. This demonstrates that NRS has strong prognostic implications regarding 284 
malnutrition-associated adverse clinical outcomes. Secondly, the association 285 
between NRS and adverse outcomes were less pronounced in patients receiving 286 
nutritional support compared to patients not receiving nutritional support, suggesting 287 
that the risk for adverse outcomes for patients with malnutrition is at least partly 288 
modifiable through provision of nutritional support.   289 
 290 
There are several findings of this study worth mentioning. Firstly, the association 291 
between malnutrition and mortality has been known for some time [1, 30, 31]. A 292 
previous retrospective observational study performed in Italy, including 5,698 patients 293 
hospitalized between from October 2015 and July 2016, showed that nutritional risk 294 
identified by NRS at time of hospital admission was a good predictor of short-term (1-, 295 
3-, 6-month) and long-term (1 year) mortality, with a doubling in mortality comparing 296 
patients scoring NRS≤3 with those NRS≥3 [24]. These finding are in line with our 297 
results, which also show an increase of 5% within 30 days and 17% within 180 days 298 
between patients with an NRS of 3 and those with ≥5 points. Importantly, we were 299 
also able to adjust our analysis for important confounders such as socio-300 
demographic factors, main admission diagnosis and comorbidities, suggesting that 301 
malnutrition has an independent negative effect on health outcomes, which is not 302 
explained by the heavier burden of disease seen in the malnourished population. Our 303 
prospective sample of patients with detailed clinical information thereby confirms 304 
results of other observational and retrospective studies with less rigorous statistical 305 
adjustment[24]. 306 
 307 
Secondly, our findings regarding secondary endpoints are also partly in line with 308 
multiple previous studies, which report associations between nutritional risk and 309 
various economic outcomes such as increased LOS [32-38], hospital readmission [4, 310 
39] and admission to an intensive care unit. The economic burden of malnutrition 311 
derives mostly from extended LOS, which leads to higher use of hospital resources 312 
and thus increased costs. A prospective cohort study of 818 patients in Singapore 313 
found an increased LOS by two days when comparing well nourished with 314 
malnourished and severely malnourished patients (using the Subjective Global 315 
Assessment SGA) [39]. In our study, we were able to adjust all analysis for 316 
confounders showing that NRS might be indeed independently associated with these 317 
economic outcomes. 318 
 319 
Thirdly, we were able to look at the association of malnutrition risk as assessed by 320 
NRS within different subgroups with different underlying main diagnosis- asking the 321 
question whether the individual situation of a patient with regard to socio-322 
demographics, admission diagnosis, and comorbidities may influence the strength of 323 
association.[40] Overall, we found little variation within these groups, suggesting that 324 
malnutrition is a risk factor across the entire medical inpatient population and the 325 
consequence of different illnesses, rather than caused by specific conditions.[41] 326 
Screening and treatment of malnutrition should, therefore, not be limited to certain 327 
patient populations, but rather include all medical inpatients.[42] This is also in line 328 
with the EFFORT trial, which demonstrates the benefits of nutritional support 329 
independent of the medical condition.[11]  330 
 331 
Fourthly, most studies looking at malnutrition and risk of impaired functional 332 
outcomes (such as quality of life or performance of activities of daily living) were 333 
carried out on a geriatric population [43, 44]. Functional impairments have an 334 
important impact on a patient’s independence, with dramatic socio-economic 335 
implications [43]. Our analysis expands the results regarding functional outcomes to 336 
a medical inpatient population, demonstrating similar results to those known from 337 
geriatrics. Both quality of life and performance of daily activities measured by the EQ-338 
5D and the Barthel scale decreased with an increasing NRS score. Interestingly, 339 
these associations were more pronounced for long-term outcomes and remained 340 
significant in the fully adjusted statistical model. The Barthel scale, for instance, was 341 
42% higher in patients scoring ≥5 points in the NRS than patients scoring 3 points. 342 
Naturally the worsening of functional outcomes due to progression of sarcopenia 343 
takes time to develop and the consequences of malnutrition only become evident 344 
only after a certain period of time.  345 
 346 
Fifth, as a new and clinically relevant main finding, we explored whether provision of 347 
nutritional support influences the association between malnutrition and adverse 348 
clinical outcomes. We focused on short-term outcomes because our intervention only 349 
looked at the initial hospital stay and not the post-discharge period. Interestingly, the 350 
association between NRS and mortality was only about half as strong in the 351 
intervention group as compared to the control group. This indicates that the adverse 352 
effects of malnutrition are at least partially modifiable. These findings again suggest 353 
that patients as being identified as at risk of malnutrition according to NRS or a 354 
similarly well-validated nutrition screening tool should receive more in-depth 355 
assessment and individualised nutritional support, if indicated.   356 
We used the NRS as a screening tool, as recommended by the European Society of 357 
Parenteral and Enteral Nutrition (ESPEN)[18]. Other screening tools for malnutrition 358 
such as the Mini Nutritional Assessment (MNA) and its shorter form (MNA-SF), as 359 
well as the malnutrition universal screening tool (MUST) have been validated for 360 
predicting mortality and adverse outcomes in previous studies, but it remains unclear 361 
which of these tools best identifies patients who would benefit from nutritional 362 
intervention [22, 23, 45]. 363 
 364 
This trial has several strengths and limitations worth mentioning. One of the strengths 365 
of this study is that it consists on a secondary analysis of a prospective randomised 366 
trial including a large unselected and heterogeneous population [12, 46, 47]. To the 367 
best of our best knowledge this is the first adequately powered study to investigate 368 
several short-term and long-term outcomes, and include functional outcomes. 369 
Furthermore, while several observational studies investigated the predictive validity 370 
of the NRS, we were the first to demonstrate that nutritional support has an influence 371 
on the association of NRS and outcome and is thus an effect modifier. We were also 372 
able to calculate multivariate regression models and adjust the analysis for important 373 
confounders.  374 
 375 
There are, however, some limitations to the underlying EFFORT trial; including the 376 
non-blinding of patients and dieticians, some variation in compliance with the 377 
nutritional protocol (with about 20% of patients not reaching their energy and protein 378 
goals which, however, is a conservative bias towards the here relevant endpoints), 379 
and the focus on one country which may limit external validity to other health care 380 
systems. Also, we only included patients with an NRS score of at least 3 points and 381 
thus have no data regarding patients with no nutritional risk as a control group. We 382 
also did not include ICU patients and surgical patients and our findings thus only 383 
applies to medical inpatients limiting external validity. Lastly the selection of co-384 
morbidities for inclusion in statistical models was based on the data collection within 385 
the initial trial. 386 
 387 
In conclusion, as it mirrors patients' individual nutritional risk, the NRS is a strong and 388 
independent risk factor for mortality and adverse outcomes - which may in turn be 389 
modified by the adequate provision of nutritional support.  390 
 391 
 392 
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Tables and Figure Legends  
Table 1. Baseline Characteristics 
Table 2. Association of NRS and clinical outcomes 
Table 3: Association of NRS with short-term Outcomes, stratified by nutritional support (intervention vs control group).   
 
Figure 1. Kaplan Meier estimate on 180-day mortality stratified by the NRS 
Time to death shown for each NRS score upon admission (p≤ 0.001)  
Figure 2. Subgroup analysis 
Subgroup analysis for sociodemographic factors and main diagnosis. The overall effect is listed as the reference group (HR 1.31; CI 
95% 1.17,1,48). “Other diagnosis” includes neuropsychological, renal, gastrointestinal and metabolic illnesses. 
Figure 3. Subgroup analysis regarding mortality and non-elective readmission  
Association of NRS and endpoints stratified by nutritional support (intervention vs control group). Adjusted Hazard ratios are shown for 
time to event outcome data, odds ratios for binary outcome data and coefficients for continuous outcomes.    
. 
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Figure 4. Subgroup analysis regarding adverse outcomes, major complications and decline in functional status 
Effects of nutritional support on primary endpoints for patients compared to the control group. Odds ratios for binary outcome data and 
coefficients for continuous outcomes.    
Figure 5. Subgroup analysis regarding Length of stay and Barthel index 
Effects of nutritional support on primary endpoints for patients compared to the control group. Coefficients are shown for continuous 
outcomes.  
 
Table 2. Association of NRS and clinical outcomes 
  
NRS 3 
(N=624) 
NRS 4 
(N=775) 
NRS ≥5 
(N=629) p-Value 
Hazard ratio 
(HR), 
Odds ratio 
(OR), 
Coefficients 
Regression analysis (not 
adjusted) 
( 95%CI and p-value) 
Regression analysis 
(adjusted) 
(95%CI and p-value) 
Primary  outcomes 
              
Short-term outcomes 
              
 All-cause mortality within 30 days 41 (6.6%)  62 (8.0%)  70 (11.1%) 0.012 HR 1.33 (1.09 to 1.61) p=0.004 1.22 (1.00 to 1.48) p=0.048 
Long-term outcomes 
              
 All-cause mortality within 180 days 101 (16.2%) 169 (21.8%) 207 (32.9%) <0.001 HR 1.51 (1.34 to 1.70) p<0.001 1.37 (1.22 to 1.55) p<0.001 
Secondary outcomes 
              
Short-term outcomes 
              
Complications 
              
Adverse outcome within 30 days  141 (22.6%)  186 (24.0%)  177 (28.1%) 0.06 OR 1.16 (1.02 to 1.32) p=0.023 1.11 (0.97 to 1.27) p=0.130 
Non-elective hospital readmission within 30 days  55 (8.8%) 64 (8.3%)  61 (9.7%) 0.64 HR 1.05 (0.87 to 1.27) p=0.589 1.03 (0.85 to 1.25) p=0.759 
Admission to the intensive care unit within 30 days  13 (2.1%) 24 (3.1%)  12 (1.9%) 0.29 OR 0.96 (0.67 to 1.38) p=0.837 1.08 (0.74 to 1.57) p=0.696 
Any major complication 45 (7.2%) 62 (8.0%) 43 (6.8%) 0.69 OR 0.97 (0.79 to 1.20) p=0.798 0.97 (0.78 to 1.21) p=0.804 
Nosocomial infection  17 (2.7%)  34 (4.4%) 28 (4.5%) 0.19 OR 1.26 (0.94 to 1.68) p=0.116 1.22 (0.91 to 1.65) p=0.182 
Major cardiovascular event 4 (0.6%) 4 (0.5%) 7 (1.1%) 0.41 OR 1.39 (0.72 to 2.69) p=0.332 1.35 (0.68 to 2.67) p=0.386 
 Acute kidney failure 20 (3.2%)  25 (3.2%)  18 (2.9%) 0.91 OR 0.94 (0.69 to 1.30) p=0.726 0.91 (0.66 to 1.27) p=0.592 
Functional outcome 
              
Mean length of stay within 30 days (days)  8.8 (6.1) 9.8 (6.7)  9.9 (6.8) 0.005 Coefficient 0.54 (0.18 to 0.90) p=0.003 0.6 (0.23 to 0.97) p=0.002 
Mean BARTHEL score (points) within 30 days 95.58 (9.12) 95.21 (9.42) 94.29 (10.6) 0.052 Coefficient -0.65 (-1.18 to -0.11) p=0.018 -0.53 (-1.07 to 0.02) p=0.059 
Decline in functional status of >10% 64 (10.3%)  90 (11.6%)   92 (14.6%) 0.052 OR 1.23 (1.04 to 1.46) p=0.018 1.16 (0.97 to 1.38) p=0.105 
Long-term outcomes 
              
Complications 
              
Non-elective hospital readmission within 180 days 168 (26.9%) 204 (26.3%) 177 (28.1%) 0.74 HR 1.11 (1.00 to 1.24) p=0.051 1.07 (0.96 to 1.19) p=0.248 
Accidental fall event within 180 days 74 (11.9%) 88 (11.4%)  58 (9.2%) 0.27 OR 0.87 (0.73 to 1.04) p=0.133 0.89 (0.74 to 1.07) p=0.200 
Fracture within 180 days 8 (1.3%) 17 (2.2%) 7 (1.1%) 0.2 OR 0.94 (0.60 to 1.47) p=0.79 0.93 (0.58 to 1.48) p=0.749 
Functional outcomes 
              
Mean EQ-5D index (points)† 0.77 (0.30) 0.75 (0.33) 0.69 (0.35) <0.001 Coefficient -0.04 (-0.06 to -0.02) p<0.001 -0.03 (-0.05 to -0.01) p=0.015 
VAS index † 60 (26)  58 (27)  55 (29) 0.007 Coefficient -2.57 (-4.23 to -0.91) p=0.002 -1.59 (-3.23 to 0.05) p=0.058 
Mean EQ-5D VAS (points) within 180 days † 56.5 (32.5) 51.5 (34.6) 44.5 (37.3) <0.001 Coefficient -6.02 (-8.07 to -3.96) p<0.001 -4.22 (-6.16 to -2.28) p<0.001 
Mean BARTHEL score (points) within 180 days † 73.1 (34.27) 68.34 (37.74) 58.08 (42.44)  <0.001  Coefficient -7.51 (-9.63 to -5.39) p<0.001 -4.49 (-6.54 to -2.45) p<0.001 
Decline in mean BARTHEL score (points) within 180 
days 284 (47.3%) 369 (49.9%)  317 (53.2%) 0.12 OR 1.13 (1.01 to 1.26) p=0.040 1.12 (0.99 to 1.27) p=0.064 
Continuous values as median and IQR, categorical/binary values as absolute number and percentage.  
NRS= Nutritional Risk Screening, EQ-5D= European Quality of Life 5 Dimensions index; VAS= visual-analogue scale 
Adjusted for sex, admission diagnosis, comorbidities, study centre and randomization. Comorbidities include: Coronary heart disease, chronic heart failure, hypertonia, stroke, chronic renal failure,  
diabetes mellitus, tumor, chronic obstructive pulmonal disease, peripheral artery disease and dementia  
HR= Hazard ratio; OR= Odds ratio 
 
Table 3: Short-term Outcomes in control versus intervention group 
  
Hazard ratio (HR), 
Odds ratio (OR), 
Coefficients 
Regression analysis 
Control (non-adjusted) 
(odds ratio and 95%CI and 
p-value) 
Regression analysis 
Intervention (non-
adjusted) 
(odds ratio and 95%CI and 
p-value) 
Regression analysis Control 
(adjusted) 
(odds ratio and 95%CI and p-
value) 
Regression analysis 
Intervention (adjusted) 
(odds ratio and 95%CI and 
p-value) 
Primary  outcomes 
          
 All-cause mortality within 30 days HR 1.43 (1.11 to 1.85) p=0.006 1.20 (0.89 to 1.61) p=0.232 1.33 (1.02 to 1.72) p=0.032 1.12 (0.83 to 1.52) p=0.454 
Secondary outcomes 
          
Complications 
          
Adverse outcome within 30 days OR 1.22 (1.02 to 1.46) p=0.026 1.10 (0.91 to 1.32) p=0.336 1.18 (0.98 to 1.42) p=0.087 1.05 (0.86 to 1.28) p=0.630 
Any major complication OR 0.98 (0.73 to 1.31) p=0.871 0.97 (0.72 to 1.31) p=0.842 0.95 (0.70 to 1.3) p=0.750 0.98 (0.72 to 1.34) p=0.914 
 Acute kidney failure OR 1.17 (0.74 to 1.85) p=0.493 0.76 (0.48 to 1.20) p=0.243 1.07 (0.67 to 1.73) p=0.771 0.75 (0.47 to 1.19) p=0.223 
Economic outcome 
          
Mean length of stay within 30 days (days) Coefficient 0.37 (-0.11 to 0.84) p=0.132 0.72 (0.17 to 1.26) p=0.010 0.42 (-0.07 to 0.91) p=0.092 0.80 (0.24 to 1.36) p=0.005 
Non-elective hospital readmission within 30 days  HR 1.14 (0.88 to 1.48) p=0.327 0.97 (0.74 to 1.26) p=0.822 1.18 (0.90 to 1.55) p=0.227 0.90 (0.69 to 1.18) p=0.436 
Admission to the intensive care unit within 30 days OR 1.00 (0.61 to 1.64) p=0.995 0.92 (0.55 to 1.57) p=0.769 1.05 (0.63 to 1.77) p=0.840 1.09 (0.62 to 1.92) p=0.753 
Functional outcome 
          
Mean BARTHEL score (points) within 30 days Coefficient -0.33 (-1.1 to 0.44) p=0.395 -0.96 (-1.72 to -0.21) p=0.012 -0.15 (-0.94 to 0.64) p=0.702 
-0.87 (-1.63 to -0.10) 
p=0.026 
Decline in functional status of >10% OR 1.17 (0.93 to 1.46) p=0.175 1.32 (1.01 to 1.72) p=0.040 1.08 (0.85 to 1.37) p=0.546 1.28 (0.97 to 1.69) p=0.078 
Continuous values as median and IQR, categorical / binary values as absolute 
number and percentage. NRS= Nutritional Risk Screening, EQ-5D= Euroquol-
5 Dimensions, VAS= Visual Analogue Scale 
*Adjusted for sex, admission diagnosis, comorbidities, study centre and 
randomization 
        
 
 
 Table 1. Baseline results of patients 
 
  
Stratified according to NRS Stratified according to Mortality 
Parameters NRS 3 NRS 4 NRS ≥5 p-Value Survivors Non-survivors p-Value 
N 624 775 629   1551 477   
Sociodemographics 
              
Mean age (years)  70.20 (15.2) 71.4 (14.9) 76.5 (10.6) <0.001 71.5 76.2 <0.001 
Age group               
  <65 years 143 (22.9%)  162 (20.9%)  50 (7.9%) <0.001 307 (19.8%) 48 (10.1%) <0.001 
  65-75 years 215 (34.5%) 247 (31.9%)  209 (33.2%) <0.001 517 (33.3%) 154 (32.3%) <0.001 
  >75 years 266 (42.6%) 366 (47.2%) 370 (58.8%)  <0.001 727 (46.9%) 275 (57.7%) <0.001 
Male sex [no.]  (%)  344 (55.1%)  402 (51.9%)   318 (50.6%) 0.250 773 (49.8%) 291 (61.0%) <0.001 
Nutritional assessment 
              
Mean Body Mass Index (kg/m2)  26.0 (5.0) 24.8 (5.3)  23.6 (5.4)  <0.001  25 (5.5) 24.2 (4.6) 0.004 
Mean bodyweight (kg)   74.2 (16.6)  71.1 (16.5) 67.1 (16.3)  <0.001 71.2 (17.0) 69.9 (15.5) 0.220 
NRS 2002 score (%) 
      
  
      
3 points         523 (33.7%) 101 (21.2%) <0.001 
4 points         606 (39.1%) 169 (35.4%) <0.001 
5 points         357 (23.0%) 167 (35.0%) <0.001 
>5 points         65 (4.2%) 40 (8.4%) <0.001 
Weight loss  - no. (%) 
              
≤5% in 3 month 434 (69.6%) 394 (50.8%)  242 (38.5%)  <0.001  858 (55.3%) 212 (44.4%) <0.001 
>5% in 3 month  94 (15.1%) 115 (14.8%) 76 (12.1%)  <0.001  200 (12.9%) 85 (17.8%) <0.001 
>5% in 2 month 70 (11.2%) 132 (17.0%) 55 (8.7%)  <0.001  182 (11.7%) 75 (15.7%) <0.001 
>5% in 1 month  26 (4.2%)  134 (17.3%) 256 (40.7%)  <0.001   311 (20.1%) 105 (22.0%) <0.001 
Loss of appetite - no. (%) 
              
No 99 (15.9%) 74 (9.5%) 56 (8.9%) <0.001 200 (12.9%) 29 (6.1%) <0.001 
Yes  525 (84.1%) 701 (90.5%)  573 (91.1%)  <0.001  1351 (87.1%) 448 (93.9%) <0.001 
Normal required food intake 
preceding week - no. (%)               
>75%  89 (14.3%) 69 (8.9%) 47 (7.5%)  <0.001 181 (11.7%) 24 (5.0%) <0.001 
50-75%  336 (53.8%) 202 (26.1%)  101 (16.1%)  <0.001  501 (32.3%) 138 (28.9%) <0.001 
25-50%  184 (29.5%)  378 (48.8%) 277 (44.0%)  <0.001  614 (39.6%) 225 (47.2%) <0.001 
<25% 15 (2.4%)  126 (16.3%) 204 (32.4%)  <0.001  255 (16.4%) 90 (18.9%) <0.001 
Severity of illness - no. (%) 
              
Very mild 33 (5.3%) 22 (2.8%) 0 (0.0%) <0.001 53 (3.4%) 2 (0.4%)  <0.001 
Mild  482 (77.2%) 548 (70.7%) 286 (45.5%)  <0.001  1021 (65.8%) 295 (61.8%) <0.001 
Moderate 105 (16.8%) 200 (25.8%)  330 (52.5%)  <0.001  458 (29.5%) 177 (37.1%) <0.001 
Severe  4 (0.6%) 5 (0.6%)  13 (2.1%)  <0.001  19 (1.2%) 3 (0.6%) <0.001 
Admission diagnosis 
              
Cardiovascular disease  78 (12.5%)   76 (9.8%)  51 (8.1%) 0.034 148 (9.5%) 57 (11.9%) 0.130 
Infection 166 (26.6%)  234 (30.2%)  213 (33.9%) 0.02 517 (33.3%) 96 (20.1%) <0.001 
Metabolic disease  20 (3.2%) 28 (3.6%)  14 (2.2%)  0.31 54 (3.5%) 8 (1.7%) 0.045 
Gastrointestinal disease 57 (9.1%)  72 (9.3%)  35 (5.6%) 0.02 136 (8.8%) 28 (5.9%) 0.042 
Renal disease 13 (2.1%)  29 (3.7%)  26 (4.1%) 0.098 52 (3.4%) 16 (3.4%) 1.000 
Cancer 91 (14.6%)  129 (16.6%) 154 (24.5%)  <0.001 188 (12.1%) 186 (39.0%) <0.001 
Lung disease 39 (6.2%) 50 (6.5%)  36 (5.7%) 0.85 98 (6.3%) 27 (5.7%) 0.600 
Neurological disease 44 (7.1%)  34 (4.4%)  17 (2.7%) 0.001 89 (5.7%) 6 (1.3%) <0.001 
Reduced general condition 71 (11.4%)  76 (9.8%) 47 (7.5%) 0.061 167 (10.8%) 27 (5.7%) <0.001 
Other  21 (3.4%) 20 (2.6%)  14 (2.2%) 0.44 42 (2.7%) 13 (2.7%) 0.980 
Comorbidity 
              
Coronary heart disease 175 (28.0%) 208 (26.8%) 183 (29.1%) 0.64 423 (27.3%) 143 (30.0%) 0.25 
Congestive heart failure 120 (19.2%)  123 (15.9%) 110 (17.5%) 0.26 239 (15.4%) 114 (23.9%) <0.001 
Hypertension 305 (48.9%)  435 (56.1%)  369 (58.7%) 0.001 839 (54.1%) 270 (56.6%) 0.34 
Stroke  51 (8.2%) 58 (7.5%)  53 (8.4%) 0.79 121 (7.8%) 41 (8.6%) 0.58 
PAD 64 (10.3%) 72 (9.3%) 50 (7.9%) 0.36 137 (8.8%) 49 (10.3%) 0.34 
Chronic kidney disease 184 (29.5%)  219 (28.3%) 238 (37.8%)  <0.001 459 (29.6%) 182 (38.2%)  <0.001  
Diabetes 124 (19.9%) 171 (22.1%)  133 (21.1%) 0.61 311 (20.1%) 117 (24.5%) 0.036 
COPD 89 (14.3%) 115 (14.8%) 99 (15.7%) 0.76  231 (14.9%)  72 (15.1%) 0.91 
Dementia 25 (4.0%)  33 (4.3%)  17 (2.7%) 0.27 55 (3.5%)  20 (4.2%) 0.51 
Malignant disease  178 (28.5%) 213 (27.5%) 276 (43.9%)  <0.001  388 (25.0%) 279 (58.5%) <0.001 
Continuous values as median and IQR, categorical / binary values as absolute number and percentage. 
NRS-2002= Nutritional Risk Screening 2002, PAD= Peripheral Artery Disease, COPD= Chronic Obstructive Pulmonary Disease 
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